重塑中国生物制药：谢氏姐弟的资本棋局

Core Viewpoint - The article discusses the strategic transformation of China National Pharmaceutical Group (referred to as "CNP") from a generic drug manufacturer to an innovative drug developer, led by the fourth-generation heirs of the Xie family, Xie Qirun and Xie Chengrun [4][5]. Group 1: Strategic Acquisitions and Investments - In January 2026, CNP announced a full acquisition of Hegia Biotech for a total price of 1.2 billion yuan, which is recognized for its innovative long-acting liver-targeted drug delivery platform [4]. - In July 2025, CNP made headlines by acquiring the tumor innovation platform Lixin Pharmaceutical for approximately $500 million, marking the largest merger in China's innovative drug sector that year [4]. - The company has engaged in a series of strategic acquisitions and investments, including the purchase of UK-based F-star and the acquisition of a controlling stake in A-share listed company Haooubo, enhancing its international research and development capabilities [4][16][17]. Group 2: Transition from Generic to Innovative Drugs - CNP's foundation is deeply rooted in the Xie family's century-old business empire, which has evolved from a small seed shop in Thailand to a multinational conglomerate [6]. - The company initially thrived in the generic drug market but faced pressure to innovate due to the 2018 drug procurement policy that significantly reduced prices of generic drugs, leading to a decline in profit margins [7][18]. - The leadership transition to Xie Qirun and Xie Chengrun marked a decisive shift towards a focus on innovative drug research and development, with a commitment to break free from the reliance on generic drugs [11][12]. Group 3: Research and Development Investments - CNP has significantly increased its R&D investment, with expenditures rising from 1.368 billion yuan in 2016 to 5.09 billion yuan in 2024, and 78% of the 3.188 billion yuan spent in the first half of 2025 directed towards innovative drug development [12]. - The company has built a research and clinical team of over 3,000 personnel, covering the entire drug development process from discovery to commercialization [12]. - CNP has established international R&D platforms through collaborations with leading global pharmaceutical companies, focusing on cutting-edge technologies such as siRNA and therapeutic vaccines [12][14]. Group 4: Financial Performance and Market Position - By mid-2025, CNP's innovative drug revenue reached 7.8 billion yuan, a year-on-year increase of 27.2%, with innovative products accounting for 44.4% of total revenue, up from 11% in 2015 [20]. - The company's overall gross margin improved from 80% in 2018 to 82.5% in the first half of 2025, reflecting enhanced operational efficiency and a shift towards higher-margin innovative products [21]. - Despite the positive trends, CNP's reliance on generic drugs for cash flow remains a concern, especially in light of ongoing price pressures from national procurement policies [21][22].